ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Jounce Therapeutics Inc

Jounce Therapeutics Inc (JNCE)

1.88
0.00
( 0.00% )
Updated: 20:00:00

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.88
Bid
2.00
Ask
1.79
Volume
-
0.00 Day's Range 0.00
1.88 52 Week Range 1.96
Previous Close
1.88
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

JNCE Latest News

Jounce Therapeutics Announces Closing of Tender Offer

CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
52-0.05-2.590673575131.931.961.8827524671.89853751CS
156-7.28-79.47598253289.1610.090.57738390263.00217773CS
260-3.81-66.95957820745.6914.840.57736610534.7233744CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ACONAclarion Inc
$ 0.4917
(70.73%)
90.35M
SGBXSafe and Green Holdings Corporation
$ 0.2321
(61.07%)
104.08M
YYGHYY Group Holding Ltd
$ 3.5605
(57.54%)
15.03M
BRFHBarfresh Food Group Inc
$ 1.46
(41.75%)
35.52M
PCSAProcessa Pharmaceuticals Inc
$ 2.264
(39.75%)
53.41M
EJHE Home Household Service Holdings Ltd
$ 0.7635
(-73.76%)
9.8M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2741
(-35.55%)
13.03M
ATNIATN International Inc
$ 19.34
(-32.66%)
191.71k
BNAIBrand Engagement Network Inc
$ 2.61
(-30.03%)
165.17k
CYCCCyclacel Pharmaceuticals Inc
$ 1.61
(-30.00%)
2.98M
SGBXSafe and Green Holdings Corporation
$ 0.2321
(61.07%)
108.48M
SQQQProShares UltraPro Short QQQ
$ 12.23
(3.56%)
92.63M
ACONAclarion Inc
$ 0.4917
(70.73%)
90.51M
TSLATesla Inc
$ 163.6375
(0.93%)
66.37M
PCSAProcessa Pharmaceuticals Inc
$ 2.264
(39.75%)
61.03M

JNCE Discussion

View Posts
Enterprising Investor Enterprising Investor 12 months ago
Jounce Therapeutics Announces Closing of Tender Offer (5/03/23)

Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC (“Concentra”), through its wholly owned subsidiary Concentra Merger Sub, Inc. (“Concentra Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 per share in cash plus a non-tradeable contingent value right (a “CVR”) per share. The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce’s closing share price immediately prior to the public disclosure of Concentra’s acquisition proposal on March 14, 2023.
The tender offer expired at 6:00 p.m., Eastern Time, on May 3, 2023. As of the expiration of the offer, 36,367,727 shares of Jounce common stock had been validly tendered and not validly withdrawn from the tender offer, representing approximately 69.09% of the outstanding shares of Jounce common stock. All conditions of the offer were satisfied or waived, and Concentra completed its acquisition of all outstanding shares of Jounce that were validly tendered and not validly withdrawn for the offer price.

Following the closing of the tender offer, Concentra Merger Sub merged with and into Jounce and all shares of Jounce common stock that had not been validly tendered were converted into the right to receive the same $1.85 per share in cash plus one CVR per share (the “Merger”). As a result of the Merger, Jounce became a wholly owned subsidiary of Concentra. Shares of Jounce common stock ceased trading on Nasdaq and Concentra intends promptly to cause such shares to be delisted. Payment will be made promptly to all former Jounce common stockholders regardless of whether they tendered their shares.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers. For more information, please visit www.jouncetx.com.

https://www.globenewswire.com/news-release/2023/05/04/2660993/0/en/Jounce-Therapeutics-Announces-Closing-of-Tender-Offer.html
👍️0
Enterprising Investor Enterprising Investor 1 year ago
Amended Schedule 14D-9 (4/24/23)

Potential upside.

On April 19, 2023, the Company executed a non-binding agreement in principle with its landlord with respect to the early termination of its lease for its headquarters (“Early Termination”). Pursuant to this non-binding agreement in principle. If the proposed Early Termination is consummated prior to the consummation of the Offer, the Final Lease Amount would be $5,250,000 and the amount of potential lease savings would be $7,350,000 (the “Potential Lease Savings”) ($12,600,000 minus $5,250,000), or approximately $0.1377 per CVR, assuming that the Company Net Working Capital (as finally determined pursuant to clause (b)(iv) of Exhibit A to the Merger Agreement) is no less than $110 million. However, since the agreement in principle with the landlord is non-binding, there is a risk that the Potential Lease Savings may not be realized if the Company cannot execute a binding agreement. Further, if at Closing, there is Company Net Working Capital of less than $110,000,000, then such shortfall would reduce the amount to be paid and stockholders under the CVR.

Risks

Certain Litigation

Subsequent to the filing of the Schedule 14D-9 and as of the date hereof, six civil actions have been filed in United States District Courts by putative stockholders of the Company: Wong v. Jounce Therapeutics, Inc., et al., Case No. 1:23-cv-03044, filed April 11, 2023 in the Southern District of New York (“S.D.N.Y.”) (the “Wong Complaint”), Diamond v. Jounce Therapeutics, Inc., et al., Case No. 1:23-cv-03053, filed April 12, 2023 (S.D.N.Y.) (the “Diamond Complaint”), Elliot v. Jounce Therapeutics, Inc., et al., Case No. 1:23-cv-03093, filed April 13, 2023 (S.D.N.Y.) (the “Elliot Complaint”), Scott v. Jounce Therapeutics, Inc., et al., Case No. 1:23-cv-00412-UNA, filed April 13, 2023 in the District of Delaware (the “Scott Complaint”), O’Dell v. Jounce Therapeutics, Inc., et al., Case No. 1:23-cv-03168, filed April 17, 2023 (S.D.N.Y) (the “O’Dell Complaint”), Wang v. Jounce Therapeutics, Inc., et al., Case No. 1:23-cv-03267, filed April 19, 2023 (S.D.N.Y) (the “Wang Complaint” and together with the Wong Complaint, the Diamond Complaint, the Elliot Complaint, the Scott Complaint and the O’Dell Complaint, the “Complaints”). All of the Complaints name the Company and the members of the Company Board as defendants.

The Complaints assert claims under the federal securities laws in connection with the Schedule 14D-9 that was filed with the SEC by the Company on April 6, 2023, alleging that the document contains materially incomplete and misleading information. The Complaints seek, among other things, an order enjoining consummation of the Transactions; rescission of the Transactions if they have already been consummated or awarding rescissory damages to plaintiff; an order directing the Company Board to file a Solicitation/Recommendation Statement that does not contain any untrue statements of material fact and that states all material facts required in it or necessary to make the statements contained therein not misleading; an award of plaintiff’s costs, including reasonable allowance for attorneys’ fees and experts’ fees; and such other and further relief as the court may deem just and proper.

Subsequent to the filing of the Schedule 14D-9 and as of the date hereof, the Company has received eight demand letters on behalf of individuals purporting to be shareholders of the Company, each generally seeking that certain information allegedly omitted from the Schedule 14D-9 be disclosed or alleged misstatements in the Schedule 14D-9 to be corrected. Additionally, subsequent to the filing of the Schedule 14D-9 and as of the date hereof, the Company received two demand letters from purported stockholders to review specified books and records of the Company relating to the Transactions.

The outcome of these lawsuits and demand letters cannot be predicted with certainty. If a preliminary injunction were to be granted it could delay or jeopardize the completion of the Transactions, and an adverse judgment granting permanent injunctive relief could indefinitely enjoin the completion of such Transactions. If additional similar complaints, or complaints relating to the demand letters disclosed herein, are filed or additional similar demand letters are received, absent new or different allegations that are material, the Company will not necessarily announce such additional filings.

https://www.sec.gov/Archives/edgar/data/1640455/000164045523000064/jnce0424202314d-9_a.htm
👍️0
Enterprising Investor Enterprising Investor 1 year ago
Jounce Acquisition: Exploring Whether It Is Worth It To Pay Up For CVR Value (4/18/23)

https://seekingalpha.com/article/4594797-jounce-acquisition-exploring-whether-worth-it-to-for-cvr-value
👍️0
Enterprising Investor Enterprising Investor 1 year ago
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights (3/27/23)

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the “CVR”).

The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce’s closing share price immediately prior to the March 14, 2023 public disclosure of Concentra’s acquisition proposal.

Following a thorough review process conducted with the assistance of its legal and financial advisors, Jounce’s Board of Directors has determined that the acquisition by Concentra – of which Tang Capital Partners, LP is the controlling shareholder – is in the best interests of all Jounce shareholders, and has unanimously approved the merger agreement.

Jounce’s Board of Directors is no longer recommending the proposed all-share merger transaction (the “Redx Business Combination”) with Redx Pharma Plc (AIM:REDX) (“Redx”). The Jounce Board of Directors has notified Redx of the withdrawal of its recommendation in favor of the Redx Business Combination and termination of the co-operation agreement dated February 23, 2023 between Jounce and Redx.

In conjunction with the merger agreement, Jounce is implementing a workforce reduction of approximately 84% of its employees. This reduction is expected to be completed within the next month and Jounce will incur restructuring costs totaling approximately $6.5 million1. The remaining Jounce employees will work to complete the sale of the Company, conduct activities to maximize the value of the CVR, work to ensure that patients on the SELECT and INNATE trials have the opportunity to continue receiving therapy with vopratelimab, JTX-8064 and pimivalimab and to otherwise ensure a smooth transition to Concentra.

Pursuant and subject to the terms of the merger agreement, a subsidiary of Concentra will commence a tender offer by April 7, 2023 to acquire all outstanding shares of Jounce for $1.85 in cash per share at closing plus a non-tradeable CVR representing the right to receive 80% of the net proceeds payable for a period of ten years post-closing from any license or disposition of Jounce’s programs effected within two years of closing and 100% of the potential aggregate value of certain specified potential cost savings.

Closing of the tender offer is subject to certain conditions, including the tender of Jounce shares representing at least a majority of the total number of outstanding shares as of immediately following the consummation of the offer; the availability of at least $110 million of cash and cash equivalents, net of any tail and closing costs, at closing, and other customary conditions. The acquisition is expected to close in the second quarter of 2023.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. For more information, please visit www.jouncetx.com.

https://www.globenewswire.com/news-release/2023/03/27/2634797/0/en/Jounce-Therapeutics-Enters-Into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-1-85-in-Cash-per-Share-Plus-Contingent-Value-Rights.html
👍️0
subslover subslover 1 year ago
I know nothing about this Company. The news crossed my desk so I decided to post here. I wish you the very best
👍️0
Invest-in-America Invest-in-America 1 year ago
JNCE: Nice "offer", but will they take it??? (Too bad the offer was for $100-per-share.)
👍️0
0whammies 0whammies 1 year ago
Trust me, I saw that yesterday. Had 4,200 shares, so it hurts to look. Had a very bad experience with GTx years ago when they announced a deal similar to the one this one did last month, so had little choice but to let go. Got deeper into Tesla, and a nice mover with the funds.

Tesla down a little, but.the mover up 100%. so, still hurts, but I'm okay with the flip.

Had hoped Jounce management would do better for shareholders from the start.....lost confidence with that earlier announcement.

GL!
👍️0
subslover subslover 1 year ago
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
March 14 2023 - 09:00PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

The Board of Directors (the “Board”) of Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (“the Proposal”) to acquire 100% of the equity of Jounce. According to the Schedule 13D filed today with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital1 is currently approximately a 10.2% shareholder of Jounce.
The Proposal consists of $1.80 in cash per share plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of certain of Jounce’s legacy programs2 (the “CVR Products”). The proposal is subject to limited confirmatory due diligence and is based on the availability of at least $130 million of cash and cash equivalents at closing, net of any tail and closing costs.

On February 23, 2023, the Company announced a recommended business combination with Redx Pharma (AIM: REDX) (“Redx”) via a proposed all share merger transaction (the “Business Combination”). The transaction is anticipated to be completed during the second quarter of 2023, subject to necessary regulatory and shareholder approvals. Shareholders are advised that no action is necessary at this time.

The Board is committed to acting in the best interests of all shareholders, consistent with its fiduciary duties. A further announcement will be made in due course.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. For more information, please visit www.jouncetx.com.

For further information, please contact:

Jounce Therapeutics, Inc
Kim Drapkin
ir@jouncetx.com T: +1-857-259-3840

Cowen (Financial Adviser to Jounce) T: +1-646-562-1010
Tanya Joseph / Erik Schuchard / Giles Roshier T: +44 (0)203 011 0460

Stern Investor Relations (Adviser to Jounce)
Julie Seidel T: +1-212-362-1200

Longacre Square Partners (Adviser to Jounce)
Dan Zacchei / Rebecca Kral
Jounce@longacresquare.com
👍️0
0whammies 0whammies 1 year ago
Still not getting the ruuuuun that others get. Not so sure this is the best thing for Jounce, though, or it would be flyyyyyiiiiing, imo. Reverse Merger on VB LT has it heading for Mars. I suppose because I own this, not that. :(

BTW, been deeeep in Jounce since early December. Was really hoping for a straight out Gilead BO. But, that was dreaming.
👍️0
81vette 81vette 1 year ago
Loading here for next leg up ,doesn’t seem like it’s going to shat all over itself like everything else is doing lately
👍️0
TheFinalCD TheFinalCD 1 year ago
https://finance.yahoo.com/news/1-biotech-firms-redx-pharma-093001762.html
👍️0
0whammies 0whammies 1 year ago
wake up, everyone!
👍️0
DH112 DH112 1 year ago
Loading upppp
👍️0
Junno1616 Junno1616 1 year ago
~ $JNCE Load the boat
👍️0
tw0122 tw0122 1 year ago
Nice move on Gilead news
👍️0
KeepOn KeepOn 2 years ago
Is this ready to take off?
👍️0
Byurwherevergirl Byurwherevergirl 3 years ago
JNCE 6.92% gain

NICE!

WG
👍️0
ClayTrader ClayTrader 4 years ago
* * $JNCE Video Chart 09-15-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
europtiger europtiger 4 years ago
17 Million float... Chart Looping Sweet

Maybelinne 13 plus soon
👍️0
now invest now invest 4 years ago
Weeeeee..... passed $11!!!!!
👍️0
europtiger europtiger 4 years ago
Weeeee
👍️0
now invest now invest 4 years ago
Passed it!!
👍️0
europtiger europtiger 4 years ago
Agile be 10 soon imo
👍️0
ClayTrader ClayTrader 4 years ago
* * $JNCE Video Chart 09-01-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
europtiger europtiger 4 years ago
And just above... lol
👍️0
europtiger europtiger 4 years ago
Volume
👍️0
europtiger europtiger 4 years ago
With the. Olive i just Bought some below 7

Lets see
👍️0
now invest now invest 4 years ago
Great news today!!
👍️0
TheFinalCD TheFinalCD 4 years ago
TYPICAL ALGO MM GAP & TRAP

THE CROOKS HAVE BEEN DOING THIS ALOT


THE TREND IS GAP & TRAP


ROBIN HOOD TRADERS


11.81-7.70

DEATH DROP

jnce



👍️0
now invest now invest 4 years ago
Nice JNCEmoving up!!! Currently up 8.99% today!!
👍️0
microcapbiotech microcapbiotech 4 years ago
JNCE at ASCO 5-29/31
👍️0
stocktrademan stocktrademan 4 years ago
JNCE buy 8.99 (8,99)

External second opinions for review:

Yahoo finance also has a good intro writeup:
https://finance.yahoo.com/quote/JNCE/profile?p=JNCE

Barchart has a quick actionable summary that is backed up with features for the more technical:
(Note: Barchart's foundation includes someone who came here from Russia.)
https://www.barchart.com/stocks/quotes/JNCE

Finviz offers a convenient way to check the analysts, news, social sentiment, and insider stock transactions
https://finviz.com/quote.ashx?t=JNCE




normal chart









log chart









normal chart








log chart






👍️0
Paul Wall Paul Wall 4 years ago
$10 on deck
👍️0
the rook the rook 4 years ago
Run done....falling knife is sharp
👍️0
ClayTrader ClayTrader 4 years ago
* * $JNCE Video Chart 12-04-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
jan_ds jan_ds 4 years ago
Gonna take a starter tomorrow..
👍️0
now invest now invest 4 years ago
To bad not more people listened!! Selling a little today!!!! Nice % profit!!
👍️0
now invest now invest 4 years ago
JNCE UP AGAIN!!!! NEVER HIT 3.60-4.00!!! Glad I added in high 4s!!! UP over 8% thus far today!!!
👍️0
now invest now invest 4 years ago
Guess retracement PREDICTION to the 4.00- 3.60 range didn't happen!!! GLad I added at the 4.80s!!!! Already sold some as I had bought some for a fast trade!!!! still have the Bulk!!! Boy if I had waited for 4 OR 3.60 !!! never would have made this cash!!!
👍️0
now invest now invest 4 years ago
You did make predictions!!! SO IGNORE ALL YOU WANT!!!! BOUGHT MORE AND CONFIDENT I'll BE MAKING OUT JUST FINE!!!!
👍️0
123tom 123tom 4 years ago
I dont make predictions.

There isnt just one single target point that must get hit. I see it as a bunch of target possibilities.
I draw technical road maps,and watch how it plays out ,while seeing what it does, notice the patterns, etc... stronger possibilities develop. like the double bottom now at 4.65 area and the key Ma, it could hold here and rally up, but there is resistance overhead (5.10-5.30 area to watch. that might cap and send the price downward. it just has to be watched. I dont make predictions.
If you want to play mind games like a troll...I can ignore you and sit in this room alone.your choice.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152315990
👍️0
123tom 123tom 4 years ago
retesting the 4.60 support again

JNCE
👍️0
now invest now invest 4 years ago
Quiet..... waiting for a bit more down to buy.... you forgot your 3.00 call
👍️0
123tom 123tom 4 years ago
Jounce bounces back into resistance

5.20-5.50 resistance fights against 5.00-4.90-4.80 aupport.

to win the next 1 dollar move.


JNCE 5 minute
👍️0
123tom 123tom 4 years ago
Looks like my forecast was pretty good

from 4 days ago. when you were laughing.

Ive been studying chart analysis for about 15 years now. getting pretty good at it. but nothing is perfect.
as long as it gets me in the ballpark,I'm ok.

It was a bubble pumped to 6 dollars, and needed to cool off. 4.70 was the target zone (4.60-4.70) that I forecasted. Now ,I'm looking for the bounce to hit resistance (5.25-5.40 and roll over and down another dollar, maybe. Target zone for the Fib math is 4.00-4.25 area. even a target around 3.85-4.00 area, but its trickier now. IF JNCE really has strong bullish momentum, it could recover and hold at 4.75 and retest 6, and not be looking to retest 4.

watching the resistance steps now.
👍️0
123tom 123tom 4 years ago
I follow price action in complex patterns

Not wanting to confuse anyone, this chart I last posted showing the 6 dollar target is not my finished target, its just the current one, based on the latest math patterns.
I never said nor expected a target hitting 2.50. I saw it held at 2.75 area and double bottomed again. It made a good rally, and so far so good for longs.

When I recently started looking at Jounce, I was forecasting a pullback target area at 3.50 , but it held at 3.60. thats why I didnt get filled in the past cycle, but I'm watching it for now.

Analysts make all kinds of target projections, and they are all way up there, but they arent describing the up and down track patterns along the way. I examine the track patterns along the way. I'm guessing you probably do as well.

Good trading to you.

Jounce has become a bubble now. pumping up, will it get hyper bubbled now, or cool off and be more normal.

👍️0
now invest now invest 4 years ago
Forecast is 10 dollars.... but as I said NOTHING GOES STRAIGHT UP !!!! BUT 2.50 is a joke!!!! Remember JNCE HAS REVENUES!!! BUT ANYONE THINKING 6 is a TOP For a TARGET WELL I wouldnt be here!!!
👍️0
123tom 123tom 4 years ago
Looks like the 6 dollar target reacted as forecasted. But how low will the pullback go is anyones technical guess.
My first reaction target is the 4.60 area.

IF the 6 dollar target is a finished rally wave, the basic Fib math for a rally 3.00 to 6.00 places the 50% Fib around 4.50.
👍️0
now invest now invest 4 years ago
You are forgetting the places JNCEis being recommended at!! Found another one last night.... SURE at some point it will back off but thus far anyone thinking that has lost out!! I think as they become more and More CF positive..... people will regret missing out!!!! But anyone thinking 4 or under should get out now IMO.... I am hoping we go sub 5 so I can buy more!!!!!
👍️0
123tom 123tom 4 years ago
looks like its heading for 6 dollars ,but its getting bubbled way too high too fast.

slam down coming , first 4.60 area (the 50ma) then 4.00-3.85

Dont laugh at the geometry and Fib math. just watch and see if it happens.
Glad for you to have a good trade going. I'd be taking profit at this weeks peak if it was me.

bubbles always get popped.
👍️0

Your Recent History

Delayed Upgrade Clock